Cell & Gene State of the Industry Briefing
ARTIFICIAL INTELLIGENCE, DIAGNOSIS, AND IMAGING
Join us virtually for the Alliance for Regenerative Medicine’s annual Cell & Gene State of the Industry Briefing, a top-level gathering for key stakeholders in the field. This webinar – which is free and open to the public – will include ARM’s annual yearly update on the sector’s progress, followed by a panel session featuring top CEOs and executives highlighting future inflection points for cell and gene therapies in the coming year.
DateJanuary 13, 2021 Online
Agenda Overview:3:00pm – 3:20pm ET
Introduction & Industry Update
Janet Lambert, CEO, Alliance for Regenerative Medicine
3:20pm – 4:00pm
Panel: Looking Ahead – What to Expect for the Cell & Gene Therapy Sector in 2021 and Beyond
Marianne De Backer, Ph.D., Member of Executive Committee and EVP, Head of Strategy and Business Development & Licensing, Pharmaceuticals Division, Bayer
Ken Mills, CEO, REGENXBIO
Adrian Rawcliffe, CEO, Adaptimmune
More speakers to be announced!
Over 500 of the cell and gene therapy field’s top stakeholders including company founders, C-level business executives, investors, media, patient advocates and academic leaders interested in learning more on the sector’s recent advances and outlook for the industry in the coming year.
Website https://alliancerm.org/arm-event/sotibriefing/
Latest News
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
LEARN MOREPfizer Acquires Amplyx Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
LEARN MOREJanux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).
LEARN MORE